Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001205205 | SCV001376446 | uncertain significance | Pityriasis rubra pilaris; Psoriasis 2 | 2022-03-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 936413). This variant has not been reported in the literature in individuals affected with CARD14-related conditions. This variant is present in population databases (rs769988602, gnomAD 0.06%), and has an allele count higher than expected for a pathogenic variant. This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 160 of the CARD14 protein (p.Leu160Val). |
Ce |
RCV001815512 | SCV002063663 | uncertain significance | not provided | 2021-10-01 | criteria provided, single submitter | clinical testing |